Amy Templeman, M Craig Miller, Martin J Cooke, Daniel J O'Shannessy, Yuwaraj Gurung, Tiago Pereira, Samuel G Peters, Mario De Piano, Manilyn Teo, Negar Khazan, Kyukwang Kim, Evan Cohen, Heather B Lopez, Franklin Alvarez, Mariacristina Ciccioli, Anne-Sophie Pailhes-Jimenez
Introduction: The Parsortix® PC1 system, Food and Drug Administration (FDA) cleared for use in metastatic breast cancer (MBC) patients, is an epitope-independent microfluidic device for the capture and harvest of circulating tumor cells from whole blood based on cell size and deformability. This report details the analytical characterization of linearity, detection limit, precision, and reproducibility for this device.
Methods: System performance was determined using K2-EDTA blood samples collected from self-declared healthy female volunteers (HVs) and MBC patients spiked with prelabeled cultured breast cancer cell lines (SKBR3, MCF7, or Hs578T). Samples were processed on Parsortix® PC1 systems and captured cells were harvested and enumerated.
Results: The system captured and harvested live SKBR3, MCF7, and Hs578T cells and fixed SKBR3 cells linearly between 2 and ~100 cells, with average harvest rates of 69%, 73%, 79%, and 90%, respectively. To harvest ≥1 cell ≥95% of the time, the system required 3, 5 or 4 live SKBR3, MCF7 or Hs578T cells, respectively. Average harvest rates from precision studies using 5, 10, and ~50 live cells spiked into blood for each cell line ranged from 63.5% to 76.2%, with repeatability and reproducibility percent coefficient of variation (%CV) estimates ranging from 12.3% to 32.4% and 13.3% to 34.1%, respectively. Average harvest rates using ~20 fixed SKBR3 cells spiked into HV and MBC patient blood samples were 75.0% ± 16.1% (%CV = 22.3%) and 68.4% ± 14.3% (%CV = 21.1%), respectively.
Conclusions: These evaluations demonstrate the Parsortix® PC1 system linearly and reproducibly harvests tumor cells from blood over a range of 1 to ~100 cells.
{"title":"Analytical performance of the FDA-cleared Parsortix<sup>®</sup> PC1 system.","authors":"Amy Templeman, M Craig Miller, Martin J Cooke, Daniel J O'Shannessy, Yuwaraj Gurung, Tiago Pereira, Samuel G Peters, Mario De Piano, Manilyn Teo, Negar Khazan, Kyukwang Kim, Evan Cohen, Heather B Lopez, Franklin Alvarez, Mariacristina Ciccioli, Anne-Sophie Pailhes-Jimenez","doi":"10.33393/jcb.2023.2629","DOIUrl":"https://doi.org/10.33393/jcb.2023.2629","url":null,"abstract":"<p><strong>Introduction: </strong>The Parsortix<sup>®</sup> PC1 system, Food and Drug Administration (FDA) cleared for use in metastatic breast cancer (MBC) patients, is an epitope-independent microfluidic device for the capture and harvest of circulating tumor cells from whole blood based on cell size and deformability. This report details the analytical characterization of linearity, detection limit, precision, and reproducibility for this device.</p><p><strong>Methods: </strong>System performance was determined using K<sub>2</sub>-EDTA blood samples collected from self-declared healthy female volunteers (HVs) and MBC patients spiked with prelabeled cultured breast cancer cell lines (SKBR3, MCF7, or Hs578T). Samples were processed on Parsortix<sup>®</sup> PC1 systems and captured cells were harvested and enumerated.</p><p><strong>Results: </strong>The system captured and harvested live SKBR3, MCF7, and Hs578T cells and fixed SKBR3 cells linearly between 2 and ~100 cells, with average harvest rates of 69%, 73%, 79%, and 90%, respectively. To harvest ≥1 cell ≥95% of the time, the system required 3, 5 or 4 live SKBR3, MCF7 or Hs578T cells, respectively. Average harvest rates from precision studies using 5, 10, and ~50 live cells spiked into blood for each cell line ranged from 63.5% to 76.2%, with repeatability and reproducibility percent coefficient of variation (%CV) estimates ranging from 12.3% to 32.4% and 13.3% to 34.1%, respectively. Average harvest rates using ~20 fixed SKBR3 cells spiked into HV and MBC patient blood samples were 75.0% ± 16.1% (%CV = 22.3%) and 68.4% ± 14.3% (%CV = 21.1%), respectively.</p><p><strong>Conclusions: </strong>These evaluations demonstrate the Parsortix<sup>®</sup> PC1 system linearly and reproducibly harvests tumor cells from blood over a range of 1 to ~100 cells.</p>","PeriodicalId":37524,"journal":{"name":"Journal of Circulating Biomarkers","volume":"12 ","pages":"26-33"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f2/17/jcb-12-26.PMC10434983.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10046658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ABSTRACT Purpose: Cataract is a major cause of blindness worldwide with a greater prevalence in developing countries like India. Owing to speculations about the relationship of various biochemical markers and cataract formation this case-control study was designed with the aim to know the impact of serum blood sugar, serum electrolytes and serum calcium on the etiopathogenesis of cataract in Kashmiri population. Methods: A total of 300 cases diagnosed with cataract and 360 healthy controls were taken for the study. Serum of all the cases and controls was analyzed for blood sugar and calcium using spectrometric techniques. Sodium and potassium were analyzed using Ion-Selective Electrode technology. All the investigations were done on ABBOTT c4000 fully automatic clinical chemistry analyzer. Results: Most of the patients in our study were ≥50 years of age having posterior subcapsular cataract. The mean levels of serum fasting blood sugar (mg/dL), serum sodium (mmol/L), serum potassium (mmol/L) and serum calcium (mg/dL) were 99.4 ± 7.7; 140.4 ± 2.5; 4.2 ± 0.5; and 8.9 ± 0.5, respectively, in cases compared to 107.7 ± 12.3; 142.9 ± 5.0; 3.8 ± 0.5; and 8.3 ± 1.7, respectively, in healthy controls. A significantly higher number of cataract cases had elevated serum glucose and sodium levels, low serum potassium and calcium levels compared to healthy controls. Conclusions: Hyperglycemia, hypernatremia, hypokalemia and hypocalcemia can independently increase the patients’ risk to cataracts. Corrections in these biochemical parameters may reduce cataract incidence.
{"title":"Impact of clinico-biochemical variations on the etiopathogenesis of cataract: a case-control study.","authors":"Tabassum Rashid, Syed Sadaf Altaf, Shabhat Rasool, Rabiya Iliyas, Sabia Rashid, Sabhiya Majid, Mosin Saleem Khan","doi":"10.33393/jcb.2023.2479","DOIUrl":"https://doi.org/10.33393/jcb.2023.2479","url":null,"abstract":"ABSTRACT Purpose: Cataract is a major cause of blindness worldwide with a greater prevalence in developing countries like India. Owing to speculations about the relationship of various biochemical markers and cataract formation this case-control study was designed with the aim to know the impact of serum blood sugar, serum electrolytes and serum calcium on the etiopathogenesis of cataract in Kashmiri population. Methods: A total of 300 cases diagnosed with cataract and 360 healthy controls were taken for the study. Serum of all the cases and controls was analyzed for blood sugar and calcium using spectrometric techniques. Sodium and potassium were analyzed using Ion-Selective Electrode technology. All the investigations were done on ABBOTT c4000 fully automatic clinical chemistry analyzer. Results: Most of the patients in our study were ≥50 years of age having posterior subcapsular cataract. The mean levels of serum fasting blood sugar (mg/dL), serum sodium (mmol/L), serum potassium (mmol/L) and serum calcium (mg/dL) were 99.4 ± 7.7; 140.4 ± 2.5; 4.2 ± 0.5; and 8.9 ± 0.5, respectively, in cases compared to 107.7 ± 12.3; 142.9 ± 5.0; 3.8 ± 0.5; and 8.3 ± 1.7, respectively, in healthy controls. A significantly higher number of cataract cases had elevated serum glucose and sodium levels, low serum potassium and calcium levels compared to healthy controls. Conclusions: Hyperglycemia, hypernatremia, hypokalemia and hypocalcemia can independently increase the patients’ risk to cataracts. Corrections in these biochemical parameters may reduce cataract incidence.","PeriodicalId":37524,"journal":{"name":"Journal of Circulating Biomarkers","volume":"12 ","pages":"1-11"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7f/2d/jcb-12-1.PMC9851602.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9132373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-07eCollection Date: 2022-01-01DOI: 10.33393/jcb.2022.2446
Diya Hasan
ABSTRACT Introduction: Serum tumor markers have emerged as an effective tool to determine prognosis and treatment efficiency in different cancer types. This study aimed to explore the chemotherapy monitoring efficiency and prognostic sensitivity of tumor-associated cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) in early (II) and late (IV) clinical stage breast cancer. Methods: CA 15-3 and CEA serum levels were assessed in 56 breast cancer patients at early (n = 26) and late (n = 30) clinical stages with these primary inclusion criteria: those who received adjuvant chemotherapy AC (adriamycin and cyclophosphamide) or AC-T (adriamycin and cyclophosphamide followed by taxane) regimens and possessed tumors negative for human epidermal growth factor receptor 2 (HER2) based on a particle-enhanced turbidimetric assay. Results: CA 15-3 had a higher elevation than CEA in the pretreatment group of breast cancer patients when compared to healthy controls. Late-stage patients showed higher positive serum levels than early-stage patients for both markers, with a preference for CA 15-3 over CEA. AC-T chemotherapy regimen treatment in both clinical stages revealed a significantly higher level of both markers as compared to the AC regime, with a preference for CA 15-3 over CEA in late stage. Both markers were significantly higher in the late-stage group as compared to early-stage groups for both chemotherapy regimens. Conclusions: CA 15-3 is more efficient as a prognostic monitoring marker than CEA and reveals a positive connection between chemotherapy regimen system and staging, with increased observability in late-stage patients.
{"title":"Diagnostic impact of CEA and CA 15-3 on chemotherapy monitoring of breast cancer patients.","authors":"Diya Hasan","doi":"10.33393/jcb.2022.2446","DOIUrl":"https://doi.org/10.33393/jcb.2022.2446","url":null,"abstract":"ABSTRACT Introduction: Serum tumor markers have emerged as an effective tool to determine prognosis and treatment efficiency in different cancer types. This study aimed to explore the chemotherapy monitoring efficiency and prognostic sensitivity of tumor-associated cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) in early (II) and late (IV) clinical stage breast cancer. Methods: CA 15-3 and CEA serum levels were assessed in 56 breast cancer patients at early (n = 26) and late (n = 30) clinical stages with these primary inclusion criteria: those who received adjuvant chemotherapy AC (adriamycin and cyclophosphamide) or AC-T (adriamycin and cyclophosphamide followed by taxane) regimens and possessed tumors negative for human epidermal growth factor receptor 2 (HER2) based on a particle-enhanced turbidimetric assay. Results: CA 15-3 had a higher elevation than CEA in the pretreatment group of breast cancer patients when compared to healthy controls. Late-stage patients showed higher positive serum levels than early-stage patients for both markers, with a preference for CA 15-3 over CEA. AC-T chemotherapy regimen treatment in both clinical stages revealed a significantly higher level of both markers as compared to the AC regime, with a preference for CA 15-3 over CEA in late stage. Both markers were significantly higher in the late-stage group as compared to early-stage groups for both chemotherapy regimens. Conclusions: CA 15-3 is more efficient as a prognostic monitoring marker than CEA and reveals a positive connection between chemotherapy regimen system and staging, with increased observability in late-stage patients.","PeriodicalId":37524,"journal":{"name":"Journal of Circulating Biomarkers","volume":" ","pages":"57-63"},"PeriodicalIF":0.0,"publicationDate":"2022-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9b/48/jcb-11-57.PMC9644433.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40704724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-03eCollection Date: 2022-01-01DOI: 10.33393/jcb.2022.2454
Ibrahim Fazal, Bhavya Shetty, Umesh Yadalam, Safiya Fatima Khan, Manjusha Nambiar
ABSTRACT Background: N-terminal-pro-brain natriuretic peptide (NT-proBNP) is an inactive hormone that is seen during inflammation and is a known biomarker of cardiovascular disease (CVD). Evidence suggests that periodontitis has a bidirectional relationship with CVD and NT-proBNP has a potential role in periodontal disease. However, there is no evidence on the impact of nonsurgical periodontal therapy (NSPT) on the levels of NT-proBNP in gingival crevicular fluid (GCF) and serum in patients with chronic periodontitis. Hence, the aim of this study was to compare the levels of NT-proBNP in GCF and serum in patients with chronic generalized periodontitis. Materials and methods: GCF and serum samples were collected in 19 patients with chronic periodontitis before and after NSPT after 6 weeks and the cumulative or reduction in values of NT-proBNP in GCF and serum was assessed. NT-proBNP levels in GCF and serum were determined by enzyme-linked immunosorbent assay. Results: The concentrations of NT-proBNP were significantly reduced in GCF and serum after NSPT. Statistically significant difference of NT-proBNP concentration between pre- and postgroups in GCF was apparent (p < 0.0001), whereas statistically nonsignificant results in NT-proBNP serum levels when compared at baseline to postoperative state with mean of 61.77 (22.6 standard deviation [SD]) preoperatively and 72.67 (51.86 SD) postoperatively (p = 0.0007) was observed. Conclusion: Significant reduction of NT-proBNP concentrations in GCF and serum in patients with chronic periodontitis subjected to NSPT was observed. This may account for a significant relation between periodontal disease, bacteremia, and CVD.
{"title":"Effectiveness of periodontal intervention on the levels of N-terminal pro-brain natriuretic peptide in chronic periodontitis patients.","authors":"Ibrahim Fazal, Bhavya Shetty, Umesh Yadalam, Safiya Fatima Khan, Manjusha Nambiar","doi":"10.33393/jcb.2022.2454","DOIUrl":"https://doi.org/10.33393/jcb.2022.2454","url":null,"abstract":"ABSTRACT Background: N-terminal-pro-brain natriuretic peptide (NT-proBNP) is an inactive hormone that is seen during inflammation and is a known biomarker of cardiovascular disease (CVD). Evidence suggests that periodontitis has a bidirectional relationship with CVD and NT-proBNP has a potential role in periodontal disease. However, there is no evidence on the impact of nonsurgical periodontal therapy (NSPT) on the levels of NT-proBNP in gingival crevicular fluid (GCF) and serum in patients with chronic periodontitis. Hence, the aim of this study was to compare the levels of NT-proBNP in GCF and serum in patients with chronic generalized periodontitis. Materials and methods: GCF and serum samples were collected in 19 patients with chronic periodontitis before and after NSPT after 6 weeks and the cumulative or reduction in values of NT-proBNP in GCF and serum was assessed. NT-proBNP levels in GCF and serum were determined by enzyme-linked immunosorbent assay. Results: The concentrations of NT-proBNP were significantly reduced in GCF and serum after NSPT. Statistically significant difference of NT-proBNP concentration between pre- and postgroups in GCF was apparent (p < 0.0001), whereas statistically nonsignificant results in NT-proBNP serum levels when compared at baseline to postoperative state with mean of 61.77 (22.6 standard deviation [SD]) preoperatively and 72.67 (51.86 SD) postoperatively (p = 0.0007) was observed. Conclusion: Significant reduction of NT-proBNP concentrations in GCF and serum in patients with chronic periodontitis subjected to NSPT was observed. This may account for a significant relation between periodontal disease, bacteremia, and CVD.","PeriodicalId":37524,"journal":{"name":"Journal of Circulating Biomarkers","volume":" ","pages":"48-56"},"PeriodicalIF":0.0,"publicationDate":"2022-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c9/10/jcb-11-48.PMC9644434.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40704723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-27eCollection Date: 2022-01-01DOI: 10.33393/jcb.2022.2370
Carmen Luz Pessuti, Deise Fialho Costa, Kleber S Ribeiro, Mohamed Abdouh, Thupten Tsering, Heloisa Nascimento, Alessandra G Commodaro, Allexya Affonso Antunes Marcos, Ana Claudia Torrecilhas, Rubens N Belfort, Rubens Belfort, Julia Valdemarin Burnier
ABSTRACT Purpose: Uveal melanoma (UM) is the most common intraocular malignant tumor in adults. Extracellular vesicles (EVs) have been extensively studied as a biomarker to monitor disease in patients. The study of new biomarkers in melanoma patients could prevent metastasis by earlier diagnosis. In this study, we determined the proteomic profile of EVs isolated from aqueous humor (AH), vitreous humor (VH), and plasma from UM patients in comparison with cancer-free control patients. Methods: AH, VH and plasma were collected from seven patients with UM after enucleation; AH and plasma were collected from seven cancer-free patients with cataract (CAT; control group). EVs were isolated using the membrane-based affinity binding column method. Nanoparticle tracking analysis (NTA) was performed to determine the size and concentration of EVs. EV markers, CD63 and TSG101, were assessed by immunoblotting, and the EV proteome was characterized by mass spectrometry. Results: Mean EV concentration was higher in all analytes of UM patients compared to those in the CAT group. In the UM cohort, the mean concentration of EVs was significantly lower in AH and plasma than in VH. In contrast, the mean size and size distribution of EVs was invariably identical in all analyzed analytes and in both studied groups (UM vs. CAT). Mass spectrometry analyses from the different analytes from UM patients showed the presence of EV markers. Conclusion: EVs isolated from AH, VH, and plasma from patients with UM showed consistent profiles and support the use of blood to monitor UM patients as a noninvasive liquid biopsy.
{"title":"Characterization of extracellular vesicles isolated from different liquid biopsies of uveal melanoma patients.","authors":"Carmen Luz Pessuti, Deise Fialho Costa, Kleber S Ribeiro, Mohamed Abdouh, Thupten Tsering, Heloisa Nascimento, Alessandra G Commodaro, Allexya Affonso Antunes Marcos, Ana Claudia Torrecilhas, Rubens N Belfort, Rubens Belfort, Julia Valdemarin Burnier","doi":"10.33393/jcb.2022.2370","DOIUrl":"https://doi.org/10.33393/jcb.2022.2370","url":null,"abstract":"ABSTRACT Purpose: Uveal melanoma (UM) is the most common intraocular malignant tumor in adults. Extracellular vesicles (EVs) have been extensively studied as a biomarker to monitor disease in patients. The study of new biomarkers in melanoma patients could prevent metastasis by earlier diagnosis. In this study, we determined the proteomic profile of EVs isolated from aqueous humor (AH), vitreous humor (VH), and plasma from UM patients in comparison with cancer-free control patients. Methods: AH, VH and plasma were collected from seven patients with UM after enucleation; AH and plasma were collected from seven cancer-free patients with cataract (CAT; control group). EVs were isolated using the membrane-based affinity binding column method. Nanoparticle tracking analysis (NTA) was performed to determine the size and concentration of EVs. EV markers, CD63 and TSG101, were assessed by immunoblotting, and the EV proteome was characterized by mass spectrometry. Results: Mean EV concentration was higher in all analytes of UM patients compared to those in the CAT group. In the UM cohort, the mean concentration of EVs was significantly lower in AH and plasma than in VH. In contrast, the mean size and size distribution of EVs was invariably identical in all analyzed analytes and in both studied groups (UM vs. CAT). Mass spectrometry analyses from the different analytes from UM patients showed the presence of EV markers. Conclusion: EVs isolated from AH, VH, and plasma from patients with UM showed consistent profiles and support the use of blood to monitor UM patients as a noninvasive liquid biopsy.","PeriodicalId":37524,"journal":{"name":"Journal of Circulating Biomarkers","volume":" ","pages":"36-47"},"PeriodicalIF":0.0,"publicationDate":"2022-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/79/50/jcb-11-36.PMC9238429.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40468389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Erfurt, Meike Hoffmeister, S. Oess, Katharina Asmus, S. Patschan, O. Ritter, D. Patschan
ABSTRACT Introduction: The prediction of acute kidney injury (AKI)-related outcomes remains challenging. Herein we prospectively quantified soluble ST2 (sST2), the circulating isoform of the IL-33 receptor, in hospitalized patients with AKI. Methods: In-hospital subjects with AKI of various etiology were identified through the in-hospital AKI alert system of the Brandenburg University hospital. sST2 was measured within a maximum of 48 hours from the time of diagnosis of AKI. The following endpoints were defined: in-hospital death, dialysis, recovery of kidney function until demission. Results: In total, 151 individuals were included in the study. The in-hospital mortality was 16.6%, dialysis therapy became mandatory in 39.7%, no recovery of kidney function occurred in 27.8%. sST2 was significantly higher in nonsurvivors (p = 0.024) but did not differ in the two other endpoints. The level of sST2 increased significantly with the severity of AKI. Further differences were detected in subjects with heart insufficiency (lower sST2), and in patients that required ICU treatment, or ventilatory therapy, or vasopressors (all higher). Conclusions: The current study suggests sST2 as biomarker of “acute distress”: it predicts post-AKI survival and substantially increases in subjects with a higher degree of cumulative morbidity under acute circumstances (e.g., ICU therapy, vasopressor administration).
{"title":"Soluble IL-33 receptor predicts survival in acute kidney injury","authors":"S. Erfurt, Meike Hoffmeister, S. Oess, Katharina Asmus, S. Patschan, O. Ritter, D. Patschan","doi":"10.33393/jcb.2022.2386","DOIUrl":"https://doi.org/10.33393/jcb.2022.2386","url":null,"abstract":"ABSTRACT Introduction: The prediction of acute kidney injury (AKI)-related outcomes remains challenging. Herein we prospectively quantified soluble ST2 (sST2), the circulating isoform of the IL-33 receptor, in hospitalized patients with AKI. Methods: In-hospital subjects with AKI of various etiology were identified through the in-hospital AKI alert system of the Brandenburg University hospital. sST2 was measured within a maximum of 48 hours from the time of diagnosis of AKI. The following endpoints were defined: in-hospital death, dialysis, recovery of kidney function until demission. Results: In total, 151 individuals were included in the study. The in-hospital mortality was 16.6%, dialysis therapy became mandatory in 39.7%, no recovery of kidney function occurred in 27.8%. sST2 was significantly higher in nonsurvivors (p = 0.024) but did not differ in the two other endpoints. The level of sST2 increased significantly with the severity of AKI. Further differences were detected in subjects with heart insufficiency (lower sST2), and in patients that required ICU treatment, or ventilatory therapy, or vasopressors (all higher). Conclusions: The current study suggests sST2 as biomarker of “acute distress”: it predicts post-AKI survival and substantially increases in subjects with a higher degree of cumulative morbidity under acute circumstances (e.g., ICU therapy, vasopressor administration).","PeriodicalId":37524,"journal":{"name":"Journal of Circulating Biomarkers","volume":"11 1","pages":"28 - 35"},"PeriodicalIF":0.0,"publicationDate":"2022-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48105750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
F. Sullivan, Agnes Tello, P. Rauchhaus, Virginia Hernandez Santiago, F. Daly
ABSTRACT Background: Patients with more severe forms of SARS-CoV-2 exhibit activation of immunological cascades. Participants (current or ex-smokers with at least 20 years pack history) in a trial (Early Diagnosis of Lung Cancer, Scotland [ECLS]) of autoantibody detection to predict lung cancer risk had seven autoantibodies measured 5 years before the pandemic. This study compared the response to Covid infection in study participants who tested positive and negative to antibodies to tumour-associated antigens: p53, NY-ESO-1, CAGE, GBU4-5, HuD, MAGE A4 and SOX2. Methods: Autoantibody data from the ECLS study was deterministically linked to the EAVE II database, a national, real-time prospective cohort using Scotland’s health data infrastructure, to describe the epidemiology of SARS-CoV-2 infection, patterns of healthcare use and outcomes. The strength of associations was explored using a network algorithm for exact contingency table significance testing by permutation. Results: There were no significant differences discerned between SARS-CoV-2 test results and EarlyCDT-Lung test results (p = 0.734). An additional analysis of intensive care unit (ICU) admissions detected no significant differences between those who tested positive and negative. Subgroup analyses showed no difference in COVID-19 positivity or death rates amongst those diagnosed with chronic obstructive pulmonary disease (COPD) with positive and negative EarlyCDT results. Conclusions: This hypothesis-generating study demonstrated no clinically valuable or statistically significant associations between EarlyCDT positivity in 2013-15 and the likelihood of SARS-CoV-2 positivity in 2020, ICU admission or death in all participants (current or ex-smokers with at least 20 years pack history) or in those with COPD or lung cancer.
{"title":"Assessment of background levels of autoantibodies as a prognostic marker for severe SARS-CoV-2 infection","authors":"F. Sullivan, Agnes Tello, P. Rauchhaus, Virginia Hernandez Santiago, F. Daly","doi":"10.33393/jcb.2022.2337","DOIUrl":"https://doi.org/10.33393/jcb.2022.2337","url":null,"abstract":"ABSTRACT Background: Patients with more severe forms of SARS-CoV-2 exhibit activation of immunological cascades. Participants (current or ex-smokers with at least 20 years pack history) in a trial (Early Diagnosis of Lung Cancer, Scotland [ECLS]) of autoantibody detection to predict lung cancer risk had seven autoantibodies measured 5 years before the pandemic. This study compared the response to Covid infection in study participants who tested positive and negative to antibodies to tumour-associated antigens: p53, NY-ESO-1, CAGE, GBU4-5, HuD, MAGE A4 and SOX2. Methods: Autoantibody data from the ECLS study was deterministically linked to the EAVE II database, a national, real-time prospective cohort using Scotland’s health data infrastructure, to describe the epidemiology of SARS-CoV-2 infection, patterns of healthcare use and outcomes. The strength of associations was explored using a network algorithm for exact contingency table significance testing by permutation. Results: There were no significant differences discerned between SARS-CoV-2 test results and EarlyCDT-Lung test results (p = 0.734). An additional analysis of intensive care unit (ICU) admissions detected no significant differences between those who tested positive and negative. Subgroup analyses showed no difference in COVID-19 positivity or death rates amongst those diagnosed with chronic obstructive pulmonary disease (COPD) with positive and negative EarlyCDT results. Conclusions: This hypothesis-generating study demonstrated no clinically valuable or statistically significant associations between EarlyCDT positivity in 2013-15 and the likelihood of SARS-CoV-2 positivity in 2020, ICU admission or death in all participants (current or ex-smokers with at least 20 years pack history) or in those with COPD or lung cancer.","PeriodicalId":37524,"journal":{"name":"Journal of Circulating Biomarkers","volume":"11 1","pages":"24 - 27"},"PeriodicalIF":0.0,"publicationDate":"2022-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44568075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hadi Sodagar, Shahriar Alipour, S. Hassani, S. Aziz, M. Ansari, Rahim Asghari
ABSTRACT Objective: Epigenetics is a quickly spreading scientific field, and the study of epigenetic regulation in various diseases such as infectious diseases is emerging. The microribonucleic acids (miRNAs) as one of the types of epigenetic processes bind to their target messenger RNAs (mRNAs) and regulate their stability and/or translation. This study aims to evaluate non-coding RNAs (ncRNAs) with a focus on miR-200c in COVID-19. In this review, we first define the epigenetics and miRNAs, and then the role of miRNAs in diseases focusing on lung diseases is explained. Finally, in this study, we will investigate the role and position of miRNAs with a focus on miR-200c in viral and severe acute respiratory syndrome–related coronavirus (SARS-CoV2) infections. Methods: Systematic search of MEDLINE, PubMed, Web of Science, Embase, and Cochrane Library was conducted for all relative papers from 2000 to 2021 with the limitations of the English language. Finally, we selected 128 articles which fit the best to our objective of study, among which 5 articles focused on the impact of miR-200c. Results: Due to the therapeutic results of various drugs in different races and populations, epigenetic processes, especially miRNAs, are important. The overall results showed that different types of miRNAs can be effective on the process of various lung diseases through different target pathways and genes. It is likely that amplified levels of miR-200c may lead to decreased angiotensin-converting enzyme-2 (ACE2) expression, which in turn may increase the potential of infection, inflammation, and the complications of coronavirus disease. Conclusion: miR-200c and its correlation with ACE2 can be used as early prognostic and diagnostic markers.
摘要目的:表观遗传学是一个快速发展的科学领域，对表观遗传学在传染病等多种疾病中的调控的研究正在兴起。微核糖核酸(miRNAs)作为表观遗传过程的一种，与靶信使rna (mrna)结合并调节其稳定性和/或翻译。本研究旨在评估非编码rna (ncRNAs)，重点关注miR-200c在COVID-19中的作用。在这篇综述中，我们首先定义了表观遗传学和miRNAs，然后重点解释了miRNAs在肺部疾病中的作用。最后，在本研究中，我们将重点研究miR-200c在病毒和严重急性呼吸综合征相关冠状病毒(SARS-CoV2)感染中的作用和位置。方法:系统检索MEDLINE、PubMed、Web of Science、Embase和Cochrane图书馆2000 - 2021年的所有相关论文，但受英语语言的限制。最后，我们选择了128篇最符合我们研究目的的文章，其中有5篇是关于miR-200c的影响。结果:由于不同药物在不同种族和人群中的治疗效果，表观遗传过程，特别是miRNAs，是重要的。综上所述，不同类型的mirna可以通过不同的靶通路和基因对各种肺部疾病的过程起作用。miR-200c水平升高可能导致血管紧张素转换酶-2 (ACE2)表达降低，进而可能增加感染、炎症和冠状病毒病并发症的可能性。结论:miR-200c及其与ACE2的相关性可作为早期预后和诊断指标。
{"title":"The role of microRNAs in COVID-19 with a focus on miR-200c","authors":"Hadi Sodagar, Shahriar Alipour, S. Hassani, S. Aziz, M. Ansari, Rahim Asghari","doi":"10.33393/jcb.2022.2356","DOIUrl":"https://doi.org/10.33393/jcb.2022.2356","url":null,"abstract":"ABSTRACT Objective: Epigenetics is a quickly spreading scientific field, and the study of epigenetic regulation in various diseases such as infectious diseases is emerging. The microribonucleic acids (miRNAs) as one of the types of epigenetic processes bind to their target messenger RNAs (mRNAs) and regulate their stability and/or translation. This study aims to evaluate non-coding RNAs (ncRNAs) with a focus on miR-200c in COVID-19. In this review, we first define the epigenetics and miRNAs, and then the role of miRNAs in diseases focusing on lung diseases is explained. Finally, in this study, we will investigate the role and position of miRNAs with a focus on miR-200c in viral and severe acute respiratory syndrome–related coronavirus (SARS-CoV2) infections. Methods: Systematic search of MEDLINE, PubMed, Web of Science, Embase, and Cochrane Library was conducted for all relative papers from 2000 to 2021 with the limitations of the English language. Finally, we selected 128 articles which fit the best to our objective of study, among which 5 articles focused on the impact of miR-200c. Results: Due to the therapeutic results of various drugs in different races and populations, epigenetic processes, especially miRNAs, are important. The overall results showed that different types of miRNAs can be effective on the process of various lung diseases through different target pathways and genes. It is likely that amplified levels of miR-200c may lead to decreased angiotensin-converting enzyme-2 (ACE2) expression, which in turn may increase the potential of infection, inflammation, and the complications of coronavirus disease. Conclusion: miR-200c and its correlation with ACE2 can be used as early prognostic and diagnostic markers.","PeriodicalId":37524,"journal":{"name":"Journal of Circulating Biomarkers","volume":"39 6","pages":"14 - 23"},"PeriodicalIF":0.0,"publicationDate":"2022-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41264562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-02-10eCollection Date: 2022-01-01DOI: 10.33393/jcb.2022.2317
Jonas Holdmann, Lukas Markert, Claudia Klinger, Michael Kaufmann, Karin Schork, Michael Turewicz, Martin Eisenacher, Stephan Degener, Nici M Dreger, Stephan Roth, Andreas Savelsbergh
ABSTRACT Introduction: Prostate cancer (PCa) is the second most frequently diagnosed cancer and the fifth most cancer-related cause of death worldwide. Various tools are used in the diagnosis of PCa, such as the Prostate-Specific Antigen (PSA) value or digital rectal examination. A final differentiation from benign prostate diseases such as benign prostatic hyperplasia (BPH) can often only be made by a transrectal prostate biopsy. This procedure carries post-procedural complications for the patients and may lead to hospitalization. Urinary exosomes contain unique components, such as microRNAs (miRNAs) with information about their original tissue. As miRNAs appear to play a role in the development of PCa, they might be useful to develop procedures that could potentially make transrectal biopsies avoidable in certain situations. Methods: The current study aimed to investigate whether miRNAs from urinary exosomes can be used to differentiate PCa from BPH. For this purpose, urine samples from 28 patients with PCa and 25 patients with BPH were collected and analysed using next-generation sequencing to obtain expression profiles. Results and conclusion: The two miRNAs hsa-miR-532-3p and hsa-miR-6749-5p showed a significant differential expression within the group of patients with PCa in a training subset of the data containing 32 patients. They were further validated on the independent test data subset containing 20 patients. Additionally, a machine learning algorithm was used to generate a miRNA pattern to distinguish the two disease entities. Both approaches seem to be suitable for the search of alternative diagnostic tools for the differentiation of benign and malignant prostate diseases.
{"title":"MicroRNAs from urinary exosomes as alternative biomarkers in the differentiation of benign and malignant prostate diseases.","authors":"Jonas Holdmann, Lukas Markert, Claudia Klinger, Michael Kaufmann, Karin Schork, Michael Turewicz, Martin Eisenacher, Stephan Degener, Nici M Dreger, Stephan Roth, Andreas Savelsbergh","doi":"10.33393/jcb.2022.2317","DOIUrl":"https://doi.org/10.33393/jcb.2022.2317","url":null,"abstract":"ABSTRACT Introduction: Prostate cancer (PCa) is the second most frequently diagnosed cancer and the fifth most cancer-related cause of death worldwide. Various tools are used in the diagnosis of PCa, such as the Prostate-Specific Antigen (PSA) value or digital rectal examination. A final differentiation from benign prostate diseases such as benign prostatic hyperplasia (BPH) can often only be made by a transrectal prostate biopsy. This procedure carries post-procedural complications for the patients and may lead to hospitalization. Urinary exosomes contain unique components, such as microRNAs (miRNAs) with information about their original tissue. As miRNAs appear to play a role in the development of PCa, they might be useful to develop procedures that could potentially make transrectal biopsies avoidable in certain situations. Methods: The current study aimed to investigate whether miRNAs from urinary exosomes can be used to differentiate PCa from BPH. For this purpose, urine samples from 28 patients with PCa and 25 patients with BPH were collected and analysed using next-generation sequencing to obtain expression profiles. Results and conclusion: The two miRNAs hsa-miR-532-3p and hsa-miR-6749-5p showed a significant differential expression within the group of patients with PCa in a training subset of the data containing 32 patients. They were further validated on the independent test data subset containing 20 patients. Additionally, a machine learning algorithm was used to generate a miRNA pattern to distinguish the two disease entities. Both approaches seem to be suitable for the search of alternative diagnostic tools for the differentiation of benign and malignant prostate diseases.","PeriodicalId":37524,"journal":{"name":"Journal of Circulating Biomarkers","volume":"11 ","pages":"5-13"},"PeriodicalIF":0.0,"publicationDate":"2022-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7f/55/jcb-11-5.PMC8844910.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39806434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-08eCollection Date: 2022-01-01DOI: 10.33393/jcb.2022.2328
Luisa Albanese, Gemma Caliendo, Giovanna D'Elia, Luana Passariello, Anna Maria Molinari, Claudio Napoli, Maria Teresa Vietri
ABSTRACT Our data confirm that intact fibroblast growth factor 23 (iFGF-23) concentration is increased in patients with chronic kidney disease (CKD) and that it increases with disease progression (stages I-V). Therefore, iFGF-23 could be considered an early biomarker in the course of chronic kidney disease-mineral bone disorder (CKD-MBD), which has several aspects that make it potentially useful in clinical practice. The availability of an automated method for iFGF-23 assay may represent an added value in the management of the patient with CKD-MBD already from the early stages of the disease, before the increase of the routinely used laboratory parameters, 1-84 parathyroid hormone (PTH) and 25-OH-vitamin D (25-OH-vitD), which occur in more advanced stages of the disease.
{"title":"Diagnostic utility of FGF-23 in mineral bone disorder during chronic kidney disease.","authors":"Luisa Albanese, Gemma Caliendo, Giovanna D'Elia, Luana Passariello, Anna Maria Molinari, Claudio Napoli, Maria Teresa Vietri","doi":"10.33393/jcb.2022.2328","DOIUrl":"https://doi.org/10.33393/jcb.2022.2328","url":null,"abstract":"ABSTRACT Our data confirm that intact fibroblast growth factor 23 (iFGF-23) concentration is increased in patients with chronic kidney disease (CKD) and that it increases with disease progression (stages I-V). Therefore, iFGF-23 could be considered an early biomarker in the course of chronic kidney disease-mineral bone disorder (CKD-MBD), which has several aspects that make it potentially useful in clinical practice. The availability of an automated method for iFGF-23 assay may represent an added value in the management of the patient with CKD-MBD already from the early stages of the disease, before the increase of the routinely used laboratory parameters, 1-84 parathyroid hormone (PTH) and 25-OH-vitamin D (25-OH-vitD), which occur in more advanced stages of the disease.","PeriodicalId":37524,"journal":{"name":"Journal of Circulating Biomarkers","volume":"11 ","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2022-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b2/95/jcb-11-1.PMC8749389.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39693209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号